Trial of QLH12016 in Patients With Metastatic Castration Resistant Prostate Cancer

Prostate Cancer Clinical Trial

Official title:

Tolerance, Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of QLH12016 in Patients With Metastatic Castration Resistant Prostate Cancer

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05973149
• Other study ID #: QLH12016-101
• Status: Not yet recruiting
• Phase: Phase 1
• Start date: August 31, 2023
• Est. completion date: January 1, 2026

Study information

• Verified date: July 2023
• Source: Qilu Pharmaceutical Co., Ltd.
• Contact: Zhisong He, Phd
• Phone: 8613910688432
• Email: wyj7074[@]sohu.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate the tolerance, safety, pharmacokinetics, and preliminary anti-tumor activity of QLH12016 in patients with metastatic castration resistant prostate cancer

Description:

Subjects will use QLH12016 for the treatment of mCRPC.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 108
• Est. completion date: January 1, 2026
• Est. primary completion date: August 31, 2025
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Voluntarily participate and sign a written informed consent form

2. Male, aged = 18 years

3. ECOG:0-1

4. Expected survival time of at least 3 months

5. Prostate adenocarcinoma confirmed by histological or cytological without neuroendocrine or small cell characters

6. Continuous treatment with luteinizing hormone releasing hormone analogue or luteinizing hormone releasing hormone antagonist (drug castration), or previous bilateral orchiectomy (surgical castration); Subjects who did not receive bilateral orchiectomy must plan to maintain effective luteinizing hormone releasing hormone analog or luteinizing hormone releasing hormone antagonist treatment throughout the study period

7. testosterone=50 ng/dL or 1.7 nmol/L

8. CRPC is defined as the occurrence of one or more of the following three events in a subject while undergoing castration treatment: ? PSA progression, defined as at least two increases in PSA levels (PSA value>1 ng/mL, interval of at least 1 week, consecutive 2 times, increase>50% from baseline); ? Disease progression as defined in RECIST v1.1; ? The progression of skeletal diseases as defined by the PCWG3 standard, where bone scans reveal = 2 or more new lesions

9. Metastatic lesion with imaging evidence. At least one target lesion exists

10. Received 1-2 lines of new endocrine therapy (such as enzalutamide, abiolone, etc.) after developing castration resistance(ArmA-C)

11. Received 0-1 line chemotherapy treatment (such as docetaxel) during the hormone sensitive period and the castration resistance period(ArmA-C)

12. Arm B: with specific biomarkers; Arm C: without specific biomarkers; Arm D: received 0 or 1 line of new endocrine therapy, and no chemotherapy during hormone sensitive and castration resistant stages

13. The functional level of important organs must meet the following requirements (no blood components, hematopoietic stimulating factors, cell growth factors, leukemic drugs, platelet enhancing drugs, etc. are allowed to be used within 7 days before obtaining laboratory examination): Absolute neutrophil count = 1.5 × 10^9/L; Platelets = 100 × 10^9/L; Hemoglobin = 100 g/L; Serum albumin = 30 g/L; AST and ALT = 2.5 × Upper limit of normal reference value (ULN), if accompanied by liver metastasis, ALT and AST = 5 × ULN; Total bilirubin = 1.5 × ULN (Gilbert syndrome= 3 × ULN); Serum creatinine = 1.5 × ULN, if >1.5 × ULN, then the creatinine clearance rate (CLcr) = 50 mL/min; LVEF>50%

14. Effective contraceptive measures from signing the informed consent to 90 days after the last use of the study drug

15. Recover from all AEs of previous anti-cancer treatment (i.e. = grade 1, according to CTCAE v5.0), excluding alopecia (any grade) and peripheral sensory nerve = grade 2, hypomagnesemia or lymphocytopenia, as well as other abnormalities that the benefit of receiving treatment is greater than the risk

Exclusion Criteria:

1. Metastasis of the central nervous system (CNS), leptomeningeal metastasis or spinal cord compression caused by metastasis (exceeding the physiological alternative dose) requiring hormone treatment

2. Radiation therapy that has irradiated more than 25% of the bone marrow was performed within 4 weeks. Palliative radiation therapy is allowed to alleviate pain caused by bone metastasis during the study period

3. Treatment with similar drugs

4. Received other clinical trial drugs or major surgeries within 4 weeks (sufficient wound healing after major surgeries must undergo clinical evaluation)

5. Systemic anti-cancer treatment within the first 2 weeks (bicalutamide, Mitomycin C or Nitroso urea 6 weeks, enzalutamide 5 weeks, and abiolone 4 weeks). Medications that maintain castration are allowed.

6. Planned bilateral orchiectomy during the study treatment

7. Inability to swallow, chronic diarrhea and bowel obstruction, or other factors affecting drug administration and absorption

8. Epilepsy or disease that can induce seizure within 12 months (including a history of transient ischemic attack, stroke, brain trauma with disorders of consciousness, etc.)

9. History of psychotropic substance abuse, alcoholism, or drug use, neurological or mental disorders, including dementia or hepatic encephalopathy

10. Any of the following conditions occurs within 12 months: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass grafting, symptomatic congestive heart failure (New York Heart Association III or IV), cerebrovascular accident, transient ischemic attack, symptomatic pulmonary embolism or other thromboembolic diseases with clinical significance

11. Any of the following conditions within 6 months: congenital long QT syndrome, torsade de pointes ventricular tachycardia, arrhythmia (including persistent ventricular tachyarrhythmia and Ventricular fibrillation), left anterior half block (double vessel block) or persistent arrhythmia above NCI-CTCAE grade 2, Atrial fibrillation of any level (in the case of Asymptomatic isolated Atrial fibrillation, grade = 2)

12. Cardiovascular diseases under poor control, including angina pectoris, pulmonary hypertension or serious cardiac rhythm or conduction abnormalities

13. QTcF>450 ms

14. Active, uncontrolled bacterial, fungal, or viral infections, including but not limited to: 1) Active hepatitis B virus (HBV), hepatitis C virus (HCV) infected persons (hepatitis B surface antigen [HBsAg] positive or hepatitis B core antibody [HBcAb] positive, HBV DNA virus copy number = 500 IU/mL, HCV antibody positive and HCV RNA higher than the detection limit of the analysis method); 2) Syphilis required treatment; 3) History of congenital immunodeficiency or organ transplantation, or HIV (HIV) positive

15. Clinically uncontrollable third space effusion, such as pleural effusion, peritoneal effusion, pericardial effusion, etc. that cannot be controlled by drainage or other measures and cannot be included in the group according to the judgment of the investigator

16. Other malignant tumors within 5 years (excluding cured basal cell skin cancer, papillary thyroid cancer, etc.)

17. Concomitant diseases seriously endangering the safety of the subject or affect the completion of the study, such as hypertension (systolic pressure = 160 mmHg and/or diastolic pressure = 100 mmHg) that cannot be controlled by two or more antihypertensive drugs, diabetes not well controlled, etc

18. History of hypertensive crisis or hypertensive encephalopathy

19. Allergy to any study drug component

20. Gastrointestinal perforation, gastrointestinal or non gastrointestinal fistula, or abdominal abscess within 6 months

21. Any life-threatening bleeding event within 3 months, including the need for blood transfusion treatment, surgery or local treatment, and continuous medication treatment

22. Subjects who may increase research related risks, interfere with the interpretation of research results, or are deemed unsuitable for inclusion by the researcher

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

Intervention

Drug:
• QLH12016
according to the scheme description

Locations

Country	Name	City	State
China	Department of Urology, Peking University First Hospital	Beijing	Beijign
China	Department of Urology, Drum Tower Hospital, Nanjing University School of Medicine	Nanjing	Jiangsu

Sponsors (1)

Lead Sponsor	Collaborator
Qilu Pharmaceutical Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Biomarkers	Using next-generation sequencing,reverse transcription DNA and quantitative polymerase chain reaction to evaluate tumor mutational burden and other signal pathway indicators	20 weeks
Primary	Arm A: Incidence of Dose Limiting Toxicities	First Cycle Dose limiting toxicities characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study drug	28 Days
Primary	Arm A:Maximum Tolerated Dose	The Maximum Tolerated Dose determined by the Incidence of Dose Limiting Toxicities	28 Days
Primary	Arm A:Recommended Phase 2 Dose	Recommended Phase 2 Dose determined by the frequency of Incidence of Dose Limiting Toxicities	28 Days
Primary	Arm A:AE	The incidence, severity and correlation with the study drug of adverse events (AEs) evaluated according to the National Cancer Institute (NCI) - General Terminology of Adverse Events (CTCAE) Version 5.0	20 weeks
Primary	Arm A:SAE	The incidence, severity and correlation with the study drug of Serious adverse event (SAE) evaluated according to the National Cancer Institute (NCI) - General Terminology of Adverse Events (CTCAE) Version 5.0	20 weeks
Primary	Arm B-D:PSA Response Rate	a decrease of = 50% in PSA levels from baseline to baseline, and reassessed PSA relief after = 3 weeks in each arm	20 weeks
Primary	Arm B-D:Objective Response Rate	the percentage of "CR/PR" subjects in each arm	20 weeks
Secondary	Cmax	The highest plasma drug concentration	20 weeks
Secondary	Tmax	The time blood drug concentration reaching Cmax	20 weeks
Secondary	AUC	The area enclosed by the drug time curve and the time axis	20 weeks
Secondary	Arm A:ORR	the percentage of "CR/PR" subjects	20 weeks
Secondary	Arm A:PSA Response Rate	a decrease of = 50% in PSA levels from baseline to baseline, and reassessed PSA relief after = 3 weeks	20 weeks
Secondary	Arm B-D:AE	The incidence, severity and correlation with the study drug of adverse events (AEs) evaluated according to the National Cancer Institute (NCI) - General Terminology of Adverse Events (CTCAE) Version 5.0	20 weeks
Secondary	Arm B-D:SAE	The incidence, severity and correlation with the study drug of Serious adverse event (SAE) evaluated according to the National Cancer Institute (NCI) - General Terminology of Adverse Events (CTCAE) Version 5.0	20 weeks
Secondary	DOR	The time between the initial evaluation of CR or PR and disease progression	20 weeks
Secondary	DCR	the percentage of "CR/PR/SD" subjects	20 weeks
Secondary	rPFS	The time between the first administration of the investigational drug and the first recording of disease progression (determined according to RECIST v1.1 and PCWG3) or the date of all-cause death (whichever occurs first)	20 weeks
Secondary	OS	The time between the first trial drug administration and patient death due to various reasons	20 weeks